Farmas USA (11747/17172)

#93969

Re: Farmas USA

15/09/16 21:45

Vendidas también todas a $8.33...

Sé que no es lo que había dicho, pero no estaba cómodo... probablemente compre un paquete menor (no más de la mitad de las plusvalías acumuladas) en los próximos días.

NVAX

Responder

#93970

Re: Farmas USA

Top 10

framus_morrigan

Seguir

15/09/16 22:03

esta NVAX halted?

edito: si, lo esta
http://www.nasdaqtrader.com/trader.aspx?id=tradehalts

Responder

#93971

Re: Farmas USA

Top 100

anaramos

Seguir

15/09/16 22:07

Nuevo proyecto de normativa sobre células en EE. UU. al que se oponen los profesionales. (Aquí tiene que haber mamoneo con las clínicas de tratamiento que han proliferado como setas.)

The initial version of the REGROW Act, S.2689, sought to eliminate Phase III clinical trials, which are needed to determine whether a new stem cell product is safe and effective. This would have allowed companies to sell new treatments with only preliminary evidence of safety and a vaguely defined “reasonable expectation of effectiveness” based on small-scale clinical studies.

A more recent version of the Act creates an expedited development pathway within the FDA solely for regenerative medicine products. Unlike other FDA accelerated review programs, any regenerative medicine product would be eligible for expedited approval regardless of whether it addresses an unmet medical need or a life-threatening illness. If REGROW is enacted, this authority would require that such products undergo a single Phase II trial and no Phase III trials.

http://www.isscr.org/home/about-us/news-press-releases/2016/2016/09/15/isscr-opposes-the-regrow-act